{"id":"ustekinumab","brandName":"Stelara","genericName":"ustekinumab","companyId":"johnson-johnson","companyName":"Johnson & Johnson","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":4,"visitCount":2,"mechanism":{"target":"p40 protein subunit of IL-12 and IL-23","modality":"Monoclonal antibody","explanation":"Ustekinumab is a monoclonal antibody that targets the p40 protein subunit shared by IL-12 and IL-23 cytokines. By binding to this subunit, ustekinumab prevents these cytokines from interacting with their receptor, IL-12Rβ1, thereby blocking the inflammatory signals they normally transmit. This helps reduce the chronic inflammation seen in conditions like Crohn’s disease and ulcerative colitis.","oneSentence":"Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.","technicalDetail":"Ustekinumab is a human IgG1κ monoclonal antibody that specifically binds to the p40 protein subunit of both IL-12 and IL-23 cytokines. This binding disrupts the interaction of these cytokines with the IL-12Rβ1 receptor, leading to the inhibition of IL-12 and IL-23 mediated signaling and cytokine cascades."},"administration":{"route":"Subcutaneous"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"14451 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"12271 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"9766 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"6605 reports"},{"date":"","signal":"PSORIASIS","source":"FDA FAERS","actionTaken":"6438 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"6036 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"5635 reports"},{"date":"","signal":"CROHN^S DISEASE","source":"FDA FAERS","actionTaken":"5584 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"5440 reports"},{"date":"","signal":"PRODUCT USE ISSUE","source":"FDA FAERS","actionTaken":"5313 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"nasopharyngitis","drugRate":"8%","_validated":true,"placeboRate":"8%"},{"effect":"upper respiratory tract infection","drugRate":"5%","_validated":true,"placeboRate":"5%"},{"effect":"headache","drugRate":"5%","_validated":true,"placeboRate":"3%"},{"effect":"fatigue","drugRate":"3%","_validated":true,"placeboRate":"2%"},{"effect":"back pain","drugRate":"1%","_validated":true,"placeboRate":"1%"},{"effect":"dizziness","drugRate":"1%","_validated":true,"placeboRate":"1%"},{"effect":"pharyngolaryngeal pain","drugRate":"1%","_validated":true,"placeboRate":"1%"},{"effect":"pruritus","drugRate":"2%","_validated":true,"placeboRate":"1%"},{"effect":"injection site erythema","drugRate":"1%","_validated":true,"placeboRate":"<1%"},{"effect":"myalgia","drugRate":"1%","_validated":true,"placeboRate":"1%"},{"effect":"depression","drugRate":"1%","_validated":true,"placeboRate":"<1%"}],"contraindications":["Clinically significant hypersensitivity to ustekinumab products or to any of the excipients in Ustekinumab-aekn."],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"event":"Infections","detail":"ustekinumab-treated subjects reported infections (1.39 per patient-years of follow-up)","severity":"serious","incidence":"27%"},{"event":"Serious infections","detail":"ustekinumab-treated subjects (0.01 per patient-years of follow-up)","severity":"serious","incidence":"0.3%"},{"event":"Malignancies excluding non-melanoma skin cancers","detail":"ustekinumab-treated subjects (0.60 per hundred patient-years of follow-up)","severity":"serious","incidence":"1.7%"},{"event":"Non-melanoma skin cancer","detail":"ustekinumab-treated subjects (0.52 per hundred patient-years of follow-up)","severity":"serious","incidence":"1.5%"}]},"trials":["NCT07077681","NCT06997055","NCT05014555","NCT02377258","NCT00741793","NCT05135221","NCT07100093","NCT03351647","NCT05542459","NCT05029921","NCT06738277","NCT01008995","NCT01945086","NCT01903317","NCT06788340","NCT07263464","NCT07268534","NCT00265122","NCT05252533","NCT00870285","NCT03006198","NCT06203158","NCT03711448","NCT04595409","NCT02786732","NCT02763969","NCT01704534","NCT05728008","NCT04435600","NCT02438787","NCT04779762","NCT01848028","NCT02330380","NCT03942120","NCT06425549","NCT06481215","NCT03651518","NCT03941132","NCT01059773","NCT06691061","NCT05696106","NCT07138898","NCT04093531","NCT05335356","NCT05092269","NCT06274554","NCT04967508","NCT07444060","NCT02561806","NCT06523647"],"indications":{"approved":[{"name":"Crohn's disease","diseaseId":"crohn's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis","diseaseId":"psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis with arthropathy","diseaseId":"psoriasis-with-arthropathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ulcerative colitis","diseaseId":"ulcerative-colitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":{"revenueYear":2024,"annualRevenue":9500,"revenueSource":"Verified: J&J 10-K","revenueCurrency":"USD","revenueConfidence":"verified"},"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT07077681","phase":"N/A","title":"Acceptability and Therapeutic Maintenance of the Biosimilar Ustekinumab After Substitution","status":"RECRUITING","sponsor":"EG Labo","isPivotal":false,"enrollment":246,"indication":"Crohn Disease (CD)","completionDate":"2027-12-31"},{"nctId":"NCT06997055","phase":"N/A","title":"ROLL'YN-UST: Etude Observationnelle de Cohorte Pour la Prise en Charge Des Patients Atteints de Pathologies Inflammatoires Chroniques traités Par Steqeyma®, un Biosimilaire de l'ustékinumab","status":"RECRUITING","sponsor":"Celltrion HealthCare France","isPivotal":false,"enrollment":225,"indication":"Crohn Disease, Plaque Psoriasis","completionDate":"2027-12-31"},{"nctId":"NCT05014555","phase":"N/A","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","isPivotal":false,"enrollment":400,"indication":"Inflammatory Bowel Diseases","completionDate":"2024-01"},{"nctId":"NCT02377258","phase":"N/A","title":"IBD Cancer and Serious Infection in Europe","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","isPivotal":false,"enrollment":13262,"indication":"IBD","completionDate":"2022-05-16"},{"nctId":"NCT00741793","phase":"N/A","title":"BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)","status":"COMPLETED","sponsor":"Janssen Inc.","isPivotal":false,"enrollment":2821,"indication":"Arthritis, Rheumatoid, Spondyloarthritis, Axial","completionDate":"2018-06-29"},{"nctId":"NCT05135221","phase":"N/A","title":"Combining Biological Therapies in Patients With Inflammatory Bowel Disease: a Finnish Multi-centre Study.","status":"COMPLETED","sponsor":"Tampere University Hospital","isPivotal":false,"enrollment":16,"indication":"IBD","completionDate":"2021-10-01"},{"nctId":"NCT07100093","phase":"N/A","title":"Prospective, Multicenter Study on the Association Between Serum Ustekinumab Levels and Clinical, Biological and Endoscopic Remission in Patients With Crohn's Disease.","status":"COMPLETED","sponsor":"Hospital Universitario La Paz","isPivotal":false,"enrollment":100,"indication":"Ustekinumab Serum Levels in Patients With Crohn´s Disease","completionDate":"2022-02-25"},{"nctId":"NCT03351647","phase":"N/A","title":"Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Re","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":18,"indication":"Crohn Disease","completionDate":"2019-09-23"},{"nctId":"NCT05542459","phase":"N/A","title":"Multi-omics to Predict Responses to Biologics in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","isPivotal":false,"enrollment":1050,"indication":"Crohn Disease, Ulcerative Colitis","completionDate":"2024-11-01"},{"nctId":"NCT05029921","phase":"Phase 4","title":"A Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With ","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":182,"indication":"Crohn Disease","completionDate":"2025-05-18"},{"nctId":"NCT06738277","phase":"Phase 1","title":"A Phase 1, Randomized, Open-label, 2-arm, Parallel Design Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, and Tolerability of Bmab 1200 -Autoinjector (Biosimilar Ustekinumab) Af","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","isPivotal":false,"enrollment":186,"indication":"Moderate to Severe Chronic Plaque Psoriasis","completionDate":"2025-07-12"},{"nctId":"NCT01008995","phase":"Phase 3","title":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Ps","status":"COMPLETED","sponsor":"Centocor, Inc.","isPivotal":true,"enrollment":322,"indication":"Psoriasis","completionDate":"2011-07"},{"nctId":"NCT01945086","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","isPivotal":false,"enrollment":79,"indication":"Dermatitis, Atopic","completionDate":"2014-12"},{"nctId":"NCT01903317","phase":"N/A","title":"Evaluation of Vitamin D Levels in Psoriasis Patients","status":"WITHDRAWN","sponsor":"University of California, Irvine","isPivotal":false,"enrollment":0,"indication":"Psoriasis","completionDate":"2015-07"},{"nctId":"NCT06788340","phase":"Phase 4","title":"MOdel-Informed Precision Dosing (MIPD) of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - An Independent Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","isPivotal":false,"enrollment":166,"indication":"Inflammatory Bowel Diseases, Crohn Disease","completionDate":"2027-11-01"},{"nctId":"NCT07263464","phase":"N/A","title":"The Association Between Tumor Necrosis Factor Superfamily Member 4 Polymorphism and Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","isPivotal":false,"enrollment":818,"indication":"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Polymorphism, Single Nucleotide","completionDate":"2025-05-31"},{"nctId":"NCT07268534","phase":"Phase 2","title":"Biologics in Folliculitis Decalvans : an Adaptative Trial Research","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":120,"indication":"Folliculitis Decalvans (FD)","completionDate":"2030-04-01"},{"nctId":"NCT00265122","phase":"Phase 2","title":"A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Centocor, Inc.","isPivotal":false,"enrollment":131,"indication":"Crohn Disease","completionDate":"2006-10"},{"nctId":"NCT05252533","phase":"Phase 1","title":"Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":31,"indication":"Juvenile Psoriatic Arthritis, Psoriasis","completionDate":"2024-01-26"},{"nctId":"NCT00870285","phase":"NA","title":"Ustekinumab Plus UVB-311nm Half-side Phototherapy in Patients With Psoriasis","status":"COMPLETED","sponsor":"Medical University of Graz","isPivotal":false,"enrollment":10,"indication":"Psoriasis","completionDate":"2011-04"},{"nctId":"NCT03006198","phase":"N/A","title":"Tracking Biologics Along the Silk Road","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","isPivotal":false,"enrollment":140,"indication":"Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative","completionDate":"2018-12-01"},{"nctId":"NCT06203158","phase":"N/A","title":"Intestinal Epithelial Fucosylation Affects the Efficacy of Ustekinumab in Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","isPivotal":false,"enrollment":50,"indication":"IBD","completionDate":"2024-02-28"},{"nctId":"NCT03711448","phase":"Phase 2","title":"Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","isPivotal":false,"enrollment":38,"indication":"Patients Relapsing Refractory Giant Cell Arteritis","completionDate":"2024-09-11"},{"nctId":"NCT04595409","phase":"Phase 3","title":"A Randomised, Double-blind, Parallel-group, Phase 3 Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Sev","status":"COMPLETED","sponsor":"Bioeq GmbH","isPivotal":true,"enrollment":392,"indication":"Plaque Psoriasis","completionDate":"2022-03-21"},{"nctId":"NCT02786732","phase":"Phase 3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"MedDerm Associates","isPivotal":true,"enrollment":15,"indication":"Psoriasis","completionDate":"2017-10"},{"nctId":"NCT02763969","phase":"Phase 1","title":"Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986202 in Healthy Subjects an","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":357,"indication":"Psoriasis","completionDate":"2016-12-15"},{"nctId":"NCT01704534","phase":"Phase 2","title":"A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica)","status":"COMPLETED","sponsor":"University Medical Center Groningen","isPivotal":false,"enrollment":20,"indication":"Hidradenitis Suppurativa","completionDate":"2014-04"},{"nctId":"NCT05728008","phase":"N/A","title":"Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.","status":"COMPLETED","sponsor":"IRCCS San Raffaele","isPivotal":false,"enrollment":100,"indication":"Ulcerative Colitis","completionDate":"2022-07-05"},{"nctId":"NCT04435600","phase":"Phase 3","title":"A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Seve","status":"COMPLETED","sponsor":"AbbVie","isPivotal":true,"enrollment":139,"indication":"Psoriasis","completionDate":"2024-10-15"},{"nctId":"NCT02438787","phase":"Phase 3","title":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiogr","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","isPivotal":true,"enrollment":315,"indication":"Axial Spondyloarthritis","completionDate":"2017-08-31"},{"nctId":"NCT04779762","phase":"NA","title":"Stelara and CDED Diet Trial for Crohn\"s Disease","status":"UNKNOWN","sponsor":"Wolfson Medical Center","isPivotal":false,"enrollment":40,"indication":"Crohn Disease","completionDate":"2026-01"},{"nctId":"NCT01848028","phase":"N/A","title":"Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","isPivotal":false,"enrollment":3500,"indication":"Psoriasis, Psoriatic-arthritis","completionDate":"2032-12"},{"nctId":"NCT02330380","phase":"N/A","title":"Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","isPivotal":false,"enrollment":26,"indication":"Psoriasis, Inflammation","completionDate":"2016-12"},{"nctId":"NCT03942120","phase":"N/A","title":"Post-Marketing Surveillance for Crohn's Disease Patients Treated With STELARA","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","isPivotal":false,"enrollment":685,"indication":"Crohn Disease","completionDate":"2022-01-14"},{"nctId":"NCT06425549","phase":"Phase 3","title":"A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to ","status":"RECRUITING","sponsor":"UCB Biopharma SRL","isPivotal":true,"enrollment":168,"indication":"Moderate to Severe Plaque Psoriasis","completionDate":"2030-11-08"},{"nctId":"NCT06481215","phase":"Phase 1","title":"An Randomized Comparative Parallel-group Trial of the Safety, Pharmacokinetics, and Immunogenicity of the Drug GNR-068 and the Drug Stelara® After Their Single Subcutaneous Administration to Healthy V","status":"COMPLETED","sponsor":"AO GENERIUM","isPivotal":false,"enrollment":122,"indication":"Healthy Volunteers","completionDate":"2022-12-20"},{"nctId":"NCT03651518","phase":"Phase 2","title":"Personalized Targeted Therapies in Inflammatory Complex Multi Organ Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":32,"indication":"Inflammatory Disease, Autoimmune Diseases","completionDate":"2025-11"},{"nctId":"NCT03941132","phase":"Phase 2","title":"Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","isPivotal":true,"enrollment":66,"indication":"Type 1 Diabetes Mellitus","completionDate":"2026-11-01"},{"nctId":"NCT01059773","phase":"Phase 4","title":"An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","isPivotal":false,"enrollment":490,"indication":"Psoriasis","completionDate":"2011-08"},{"nctId":"NCT06691061","phase":"N/A","title":"Real-life Comparative Effectiveness of Vedolizumab, Ustekinumab and JAK Inhibitors in Patients with Ulcerative Colitis After Anti-TNFα Failure or Intolerance","status":"RECRUITING","sponsor":"Humanitas Clinical and Research Center","isPivotal":false,"enrollment":450,"indication":"Ulcerative Colitis (Disorder)","completionDate":"2024-12-31"},{"nctId":"NCT05696106","phase":"N/A","title":"Risk of Incident Immune-mediated Inflammatory Diseases (IMID) in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":750000,"indication":"Inflammatory Disease","completionDate":"2024-01-15"},{"nctId":"NCT07138898","phase":"Phase 2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","isPivotal":false,"enrollment":80,"indication":"Rheumatic Disease","completionDate":"2027-09"},{"nctId":"NCT04093531","phase":"Phase 1","title":"Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"University of Rochester","isPivotal":false,"enrollment":12,"indication":"Primary Sjögren Syndrome","completionDate":"2022-05-11"},{"nctId":"NCT05335356","phase":"Phase 3","title":"A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","isPivotal":true,"enrollment":384,"indication":"Moderate to Severe Chronic Plaque Psoriasis","completionDate":"2023-11-15"},{"nctId":"NCT05092269","phase":"Phase 3","title":"A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","isPivotal":true,"enrollment":159,"indication":"Crohn Disease, Colitis, Ulcerative","completionDate":"2028-03-15"},{"nctId":"NCT06274554","phase":"Phase 3","title":"A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","isPivotal":true,"enrollment":120,"indication":"Crohn's Disease, Inflammatory Bowel Diseases","completionDate":"2029-12"},{"nctId":"NCT04967508","phase":"Phase 3","title":"A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SB17 (Proposed Ustekinumab Biosimilar) Compare","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","isPivotal":true,"enrollment":503,"indication":"Psoriasis, Moderate to Severe Plaque Psoriasis","completionDate":"2022-11-25"},{"nctId":"NCT07444060","phase":"N/A","title":"Efficacy of Guselkumab Versus Ustekinumab in Stricturing Crohn's Disease: A Multicenter, Prospective, Observational Cohort Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":100,"indication":"CD - Crohn's Disease, Stricture; Bowel","completionDate":"2029-12-31"},{"nctId":"NCT02561806","phase":"Phase 3","title":"A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":302,"indication":"Plaque Psoriasis","completionDate":"2017-10"},{"nctId":"NCT06523647","phase":"N/A","title":"Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components","status":"RECRUITING","sponsor":"Kazakhstan Scientific Society for Study of intestine diseases","isPivotal":false,"enrollment":150,"indication":"Crohn's Disease","completionDate":"2025-12"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-05-21T00:00:00.000Z","mah":"CENTOCOR ORTHO BIOTECH INC","brand_name_local":null,"application_number":"BLA125261"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-10-18T00:00:00.000Z","mah":"ALVOTECH USA INC","brand_name_local":null,"application_number":"BLA761343"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-28T00:00:00.000Z","mah":"CELLTRION, INC.","brand_name_local":null,"application_number":"BLA761338"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-09-25T00:00:00.000Z","mah":"AMGEN INC","brand_name_local":null,"application_number":"BLA761331"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-09-25T00:00:00.000Z","mah":"AMGEN INC","brand_name_local":null,"application_number":"BLA761285"},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":"EMEA/H/C/005918"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Steqeyma","application_number":null}],"trialStats":{"total":43,"withResults":10},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ustekinumab","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:18:48.366637+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:18:56.186060+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:18:46.997782+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ustekinumab","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:18:57.050235+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:44.850796+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:44.850854+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:18:58.660677+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Ustekinumab products are human IgG1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab products were shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by di","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:19.936708+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-23 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:57.612113+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201835/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:57.522504+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the label: Infections [see Warnings and Precautions ( 5.1 )] Malignancies [see Warnings and Precautions ( 5.4 )] Serious Hypersensitivity Reactions [see Warnings and Precautions ( 5.5 )] Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions ( 5.6 )] Noninfectious Pneumonia [see Warnings and Precautions ( 5.8 )] Most common adverse reactions are: Psoriasis and Psoriatic Arthritis (≥3","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:52.042634+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:55.143591+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761343","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:44.850865+00:00"}},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:19:57.096642+00:00","fieldsConflicting":0,"overallConfidence":0.95},"pharmacokinetics":{"tmax":"7-13.5 days (subcutaneous); 8.5 days (subcutaneous, healthy subjects)","halfLife":"Not specified in text","metabolism":"Not specified in text","elimination":"Not specified in text","bioavailability":"Not specified in text"},"crossReferences":{"chemblId":"CHEMBL1201835"},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}